N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide | 876148-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide
• 英文别名: Tert-butyl 2-[[[2-(4-chlorophenyl)-4-methyl-1,3-thiazole-5-carbonyl]amino]methyl]morpholine-4-carboxylate
• CAS: 876148-25-3
• 化学式: C₂₁H₂₆ClN₃O₄S
• 分子量: 451.974
• InChiKey: FAUGHLLHCXGZIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide 在 盐酸 、 copper diacetate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 methyl 3-[2-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminomethyl]morpholin-4-yl]benzoate
  参考文献：
  名称：

  Discovery of cyclic amine-substituted benzoic acids as PPARα agonists

  摘要：

  A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPAR alpha agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido] piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARa agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.002
• 作为产物：
  描述：

  4-Boc-2-(氨甲基)吗啉 、 2-(4-氯苯基)-4-甲基-1,3-噻唑-5-羧酸 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide
  参考文献：
  名称：

  Discovery of cyclic amine-substituted benzoic acids as PPARα agonists

  摘要：

  A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPAR alpha agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido] piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARa agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.002

文献信息

• Novel Cyclic Amino Benzoic Acid Derivative
  申请人：Nomura Masahiro

  公开号：US20070249580A1

  公开（公告）日：2007-10-25

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C 1 -C 4 alkylene, C 2 -C 4 alkenylene, C 2 -C 4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH 2 ) n — (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂，在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的药物组合物。其中，循环氨基苯甲酸衍生物的一般式（1）表示为[其中，环Ar表示可能具有取代基的芳基；Y表示C1-C4烷基、C2-C4烯基、C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能带有卤原子取代的低烷基或类似物；R表示氢原子或低烷基，而—COOR代替环W的结合位置的邻位或间位]或其药学上可接受的盐。
• NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP1780210A1

  公开（公告）日：2007-05-02

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及作为人过氧化物酶体增殖激活受体（PPAR）激动剂，特别是作为人PPARα同工酶的激动剂，对脂质代谢异常、糖尿病等治疗有效的环氨基苯甲酸衍生物及其加成盐，以及含有这些化合物的药物组合物。 由通式（1）代表的环氨基苯甲酸衍生物 [其中，环 Ar 代表芳基，可具有取代基等；Y 代表 C1-C4 亚烷基、C2-C4 亚烯基、C2-C4 亚炔基等；Z 代表氧原子、硫原子或 - (CH2)n- （n 代表 0、1 或 2）；X 代表氢原子、卤素原子、可被卤素原子取代的低级烷基或类似物；R 代表氢原子或低级烷基，-COOR 取代环 W 结合位的正位或甲位]或其药学上可接受的盐。
• US7902367B2
  申请人：——

  公开号：US7902367B2

  公开（公告）日：2011-03-08
• Discovery of cyclic amine-substituted benzoic acids as PPARα agonists
  作者：Masahiro Nomura、Kazuhiro Yumoto、Takehiro Shinozaki、Shigeki Isogai、Yasuo Takano、Koji Murakami

  DOI：10.1016/j.bmcl.2011.11.002

  日期：2012.1

  A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPAR alpha agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido] piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARa agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides. (C) 2011 Elsevier Ltd. All rights reserved.